US publication Stat News reported certain discrepancies in clinical trial of Covaxin, on November 15, 2022. One of directors of Covaxin’s maker Bharat Biotech, Krishna Mohan, blamed it on ‘political pressure’ to rush the vaccine while talking to the publication. However, in a statement issued a day later, the company claimed the pressure was all ‘ internal’ and not external. The statement also said the company had proceeded with phase-3 trial on the basis of phase-1 results and preclinical studies itself — without the mandatory phase 2 results.
Watch this video explainer to know more.